Literature DB >> 28336133

Comparison of Cobas® HPV and Anyplex™ II HPV28 assays for detecting and genotyping human papillomavirus.

Christophe Pasquier1, Karine Sauné2, Stéphanie Raymond2, Jérôme Boisneau3, Monique Courtade4, Jacques Izopet2.   

Abstract

Persistent infection with high-risk human papillomavirus (HPV-HR) is a recognized cause of cervical cancer. The aim of this study was to compare analytical and clinical performances of the Cobas® HPV and Anyplex™ II HPV28 assays for HPV detection and genotyping. A total of 94 cervical samples were tested. For HPV-HR, the results agreed very well (94.68%), with 100% agreement when detecting CIN2+. The Anyplex™ II HPV28 assay detected more genotypes than the Cobas® HPV Test, but their clinical performances were similar.
Copyright © 2016. Published by Elsevier Inc.

Entities:  

Keywords:  Anyplex™ II HPV28; HPV genotyping; Human papillomavirus; Real-time PCR

Mesh：

Year:  2016        PMID： 28336133     DOI： 10.1016/j.diagmicrobio.2016.08.022

Source DB:  PubMed          Journal:  Diagn Microbiol Infect Dis        ISSN： 0732-8893            Impact factor:   2.803


  4 in total

1.  Comparison of Seegene Anyplex II HPV28 assay with BD Onclarity HPV assay for human papillomavirus genotyping.

Authors:  Moonsik Kim; Jinhee Kim; Nora Jee-Young Park; Ji Young Park
Journal:  PLoS One       Date:  2022-07-08       Impact factor: 3.752

2.  Unusual and unique distribution of anal high-risk human papillomavirus (HR-HPV) among men who have sex with men living in the Central African Republic.

Authors:  Ralph-Sydney Mboumba Bouassa; Marcel Mbeko Simaleko; Serge Police Camengo; Christian Diamant Mossoro-Kpinde; David Veyer; Mathieu Matta; Leman Robin; Jean De Dieu Longo; Gérard Grésenguet; Hélène Péré; Jean-François Meye; Laurent Belec
Journal:  PLoS One       Date:  2018-05-24       Impact factor: 3.240

3.  High prevalence of cervical high-risk human papillomavirus infection mostly covered by Gardasil-9 prophylactic vaccine in adult women living in N'Djamena, Chad.

Authors:  Ralph-Sydney Mboumba Bouassa; Zita Aleyo Nodjikouambaye; Damtheou Sadjoli; Chatté Adawaye; Hélène Péré; David Veyer; Mathieu Matta; Leman Robin; Serge Tonen-Wolyec; Ali Mahamat Moussa; Donato Koyalta; Laurent Belec
Journal:  PLoS One       Date:  2019-06-03       Impact factor: 3.240

4.  Clinical performance of Anyplex II HPV28 by human papillomavirus type and viral load in a referral population.

Authors:  Ingrid Baasland; Pål R Romundstad; Maj Liv Eide; Christine M Jonassen
Journal:  PLoS One       Date:  2019-01-23       Impact factor: 3.240
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.